Parabilis Medicines

San Francisco – October 15, 2026 -- Benchling launched Science Foundries, a product that lets R&D teams run entire scientific processes with agents and scientists working from the same data, and made it available to its customers the same day.

Teams select a process or goal, such as producing proteins, optimizing a lead or improving a manufacturing process. They then define which steps agents run and where scientists must approve. Agents execute and monitor work, coordinate handoffs and flag key decisions to scientists.

Benchling has spent the past 18 months building AI into its platform. The company says agents are the fastest-growing capability it has released. Science Foundries extend agents from individual tasks to complete workflows.

Toronto – September 28, 2026 -- Sixty Degree Capital (SDC) saw five portfolio companies complete initial public offerings in 2026, including the largest IPO in history and the largest biotech IPO on record. SpaceX, Parabilis Medicines, Cerebras, HawkEye 360 and Lime each began trading on U.S. exchanges between May and July, while GrubMarket has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission.

SpaceX offering reaches approximately US$75 billion, the largest IPO ever recorded

SpaceX's public listing totaled roughly US$75 billion, according to the Toronto-based venture capital firm, marking the largest IPO in history. The offering anchors a wave of 2026 public-market exits across SDC's technology and healthcare portfolio.